Search hospitals > British Columbia > VANCOUVER

G.I. Research Institute

Claim this profile
VANCOUVER, British Columbia V6Z 2K5
Global Leader in Crohn's Disease
Global Leader in Ulcerative Colitis
Conducts research for Colitis
Conducts research for Inflammatory Bowel Disease
Conducts research for Chronic Hepatitis B
89 reported clinical trials
4 medical researchers
Photo of G.I. Research Institute in VANCOUVERPhoto of G.I. Research Institute in VANCOUVERPhoto of G.I. Research Institute in VANCOUVER

Summary

G.I. Research Institute is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Colitis, Inflammatory Bowel Disease, Chronic Hepatitis B and other specialties. G.I. Research Institute is involved with conducting 89 clinical trials across 65 conditions. There are 4 research doctors associated with this hospital, such as Gregory Rosenfeld, Hin Hin Ko, MD, Alnoor Ramji, MD, and Brian Bressler, MD.

Top PIs

Clinical Trials running at G.I. Research Institute

Crohn's Disease
Ulcerative Colitis
Inflammatory Bowel Disease
Alpha-1 Antitrypsin Deficiency
Eosinophilic Esophagitis
Colonic Polyps
Colon Lesions
Colon Polyps
Colon Adenomas
Psychogenic Colitis
Image of trial facility.

Gut Microbiome Analysis

for Crohn's Disease

The goal of this prospective observational study is to determine if specific microbiome signatures can predict therapeutic responses in adult patients with Crohn's disease (CD), a form of inflammatory bowel disease (IBD), living in British Columbia, Canada. The main questions this study seeks to answer are: 1. Can microbiome signatures across different sample types (fecal, intestinal washings, and intestinal epithelial biopsies) predict response to therapy in CD? 2. How do microbiome profiles differ between active and quiescent CD and non-IBD controls? Researchers will compare microbiome signatures in patients with active and inactive CD as well as non-IBD controls to see if there are any microbial signatures that predict response to therapy. Participants will: 1. Provide fecal and blood samples. 2. Undergo intestinal washings and intestinal epithelial biopsy specimens taken during routine colonoscopy. 3. Participate in a longitudinal follow-up over 12 months to monitor clinical, biochemical, and endoscopic responses to therapy.
Recruiting1 award N/A10 criteria
Image of trial facility.

TAK-279

for Crohn's Disease

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.
Recruiting0 awards Phase 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at G.I. Research Institute?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security